Medeva Fluvirin Production Returns To Market-Demand Level
Executive Summary
Production of Medeva's influenza vaccine Fluvirin has returned to levels of market demand following improvements in the manufacturing process, the company said.
You may also be interested in...
Powderject Moves Into Marketing Phase Via Medeva Vaccines Acquisition
Powderject's acquisition of Medeva's vaccines business moves the company from the research phase into the marketing of six products, one of which is sold in the U.S.
Powderject Moves Into Marketing Phase Via Medeva Vaccines Acquisition
Powderject's acquisition of Medeva's vaccines business moves the company from the research phase into the marketing of six products, one of which is sold in the U.S.
Celltech Medeva Hepacare Hep B Vaccine Targeted For End-2000 U.K. Launch
Celltech Medeva's three-antigen hepatitis B vaccine Hepacare is slated for a late-2000 U.K. launch following a March 16 recommendation by EMEA's Committee for Proprietary Medicinal Products.